Agricultural Biotechnology Coordination Act
- Bill Number
- S. 2692
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Agriculture and Food
- Status
- Introduced
- Latest Action
- 2025-09-03: Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
- Last Updated
- 2025-09-22T19:25:47Z
AI-Generated Summary
Purpose
The Agricultural Biotechnology Coordination Act (S. 2692) aims to strengthen the U.S. Department of Agriculture's (USDA) focus on biotechnology by creating a dedicated office to coordinate policies, research, and activities related to agricultural biotechnology, biomanufacturing, synthetic biology, and emerging technologies. This ensures more effective oversight and integration of these technologies in agriculture.
Key Provisions
- Establishment of the Office: The Secretary of Agriculture must create the Office of Biotechnology Policy within the USDA, headed by a Director who reports directly to the Secretary (or a designee).
- Core Duties:
- Develop and coordinate USDA policies and activities on biotechnology, covering research and development, communication/education/extension services, regulation and labeling, and commercialization/use/trade.
- Support other USDA offices and agencies in meeting their biotechnology-related legal responsibilities.
- Perform additional duties as required by law or deemed necessary by the Secretary.
- Interagency Coordination: The Office will lead efforts to align activities with other federal agencies, such as the Environmental Protection Agency (EPA) and Food and Drug Administration (FDA), as well as relevant state agencies.
- Consultation Requirements: The Office must consult with affected parties, including biotechnology developers, academics, agricultural producers, and other entities impacted by biotechnology policies.
Significant Changes to Existing Law
- Amends the Department of Agriculture Reorganization Act of 1994 by inserting a new Section 223, which mandates the creation and prioritization of the Office of Biotechnology Policy.
- Adds a conforming amendment to Section 296(b) of the 1994 Act, explicitly granting the Secretary authority to implement the new office's functions.
These changes introduce a centralized structure for biotechnology that did not previously exist, shifting from decentralized handling across USDA offices to a unified, prioritized approach.
Potential Impacts
- On Government Agencies: Enhances coordination within USDA and between federal agencies (e.g., EPA and FDA), potentially streamlining regulatory processes for biotechnology products and reducing overlaps or delays in approvals.
- On Citizens and Agricultural Producers: Could lead to faster innovation in crops and farming practices through better-supported research and education, benefiting farmers with improved tools for productivity and sustainability; however, it may influence labeling and trade rules affecting consumer choices.
- On International Relations: Supports smoother commercialization and trade of U.S. biotechnology products by aligning domestic policies, potentially strengthening the U.S. position in global agricultural markets, though it could require harmonization with international standards on biotech safety and labeling.
Main Stakeholders Affected
- USDA and Federal Agencies: Primary implementers, including the new Office, EPA, and FDA, which will collaborate on biotechnology oversight.
- Agricultural Producers and Farmers: Directly impacted through policies on research, regulation, and trade that affect crop development and market access.
- Biotechnology Developers and Industry: Benefit from coordinated support for commercialization and consultation in policy-making.
- Academics and Researchers: Involved in consultations and gain from enhanced research coordination.
- State Agencies and Consumers: Indirectly affected via interagency alignment on regulation, labeling, and education.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces the USDA's statutory authority under the 1994 Reorganization Act without altering broader regulatory frameworks (e.g., those under the EPA or FDA for biotech approvals). The consultation mandate promotes transparency and stakeholder input, aligning with administrative law principles of public participation.
- Constitutional: No direct challenges; it operates within Congress's enumerated powers to regulate interstate commerce and agriculture, potentially supporting efficient federal administration under the Necessary and Proper Clause.
- Political: Signals bipartisan support (introduced by Senators Padilla and Young) for advancing agricultural innovation amid growing debates on biotechnology's role in food security and environmental sustainability. It could influence future funding priorities for USDA programs but may spark discussions on balancing innovation with public concerns over genetically modified organisms (GMOs).
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-09-03: Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
- 2025-09-03: Introduced in Senate
Bill Versions
- Agricultural Biotechnology Coordination Act — issued 2025-09-03 — PDF (4 pages)